Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates

Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the

10 Best Russell 2000 Stocks to Invest In According to Hedge Funds.

On May 7, Stoke Therapeutics, Inc. (NASDAQ:STOK) reported Q1 results and business updates. The company stated that four years of data from “Phase 1/2a open-label extension” studies revealed statistically meaningful gains in cognition and behavior, along with recurrent seizure drops from baseline. “Zorevunersen” remained generally well tolerated, with some patients treated for more than five years.

Chief Executive Officer and Director Ian F. Smith said the data “suggest that zorevunersen may change the course of Dravet syndrome,” noting seizure reductions and potential developmental benefits.UnitedHealth Group (UNH) Hit by Medicare Reimbursement Concerns

The company also said “Phase 3 EMPEROR” enrollment of approximately 150 patients is expected to be completed in June 2026. It supports mid-2027 data and a planned rolling US NDA submission in Q1 of 2027.

As of March 31, 2026, Stoke Therapeutics, Inc. (NASDAQ:STOK) had $411 million in cash and investments, including $80.7 million raised by ATM sales. It is funding operations into 2028.

Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company that conducts research and develops treatments for genetic diseases.

While we acknowledge the potential of STOK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments